Bio-TechneMEX:TECH 83 Cyclically Adjusted PS Ratio is 7.69 as of Jul. 11, 2026, which is 45% below its 10-year median of 14.03. GuruFocus rates MEX:TECH with a GF Score™ of 83/100 and a GF Value™ of MXN1,111.68. The stock has 8 warning signs investors should review. Among 538 Biotechnology companies, Bio-Techne ranks worse than 64.87% on this metric.
The historical rank and industry rank for Bio-Techne's Cyclically Adjusted PS Ratio or its related term are showing as below:
MEX:TECH'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.37 Med: 14.03 Max: 34.02
Current: 10.46
During the past years, Bio-Techne's highest Cyclically Adjusted PS Ratio was 34.02. The lowest was 6.37. And the median was 14.03.
MEX:TECH's Cyclically Adjusted PS Ratio is ranked worse than 64.87% of 538
companies
in the Biotechnology industry
Industry Median: 5.85
vs MEX:TECH: 10.46
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Bio-Techne's adjusted revenue per share data for the three months ended in Mar. 2026 was MXN35.677. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN141.83 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Bio-Techne (MEX:TECH) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Bio-Techne Cyclically Adjusted PS Ratio Related Terms
Bio-Techne Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TECH vs ARWR, CYTK, KRYS: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Cyclically Adjusted PS Ratio falls into.
Bio-Techne Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Bio-Techne's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 7.69 mean?
Bio-Techne (MEX:TECH) has a Cyclically Adjusted PS Ratio of 7.69 as of Jul. 11, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors. This is 45% below median its historical median of 14.03. Over the past decade, Bio-Techne's Cyclically Adjusted PS Ratio has ranged from 6.37 to 34.02. According to the industry distribution chart, Bio-Techne ranks #349 out of 538 companies in the Biotechnology industry, placing it in the top 64.9%.
Is Bio-Techne's Cyclically Adjusted PS Ratio too high?
Bio-Techne's current Cyclically Adjusted PS Ratio of 7.69 is 45% below median its 10-year median of 14.03. Over the past 10 years, this metric has ranged from a low of 6.37 to a high of 34.02. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.85. Bio-Techne's value of 7.69 is 31.5% above this industry median. Based on the distribution chart, Bio-Techne ranks #349 out of 538 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bio-Techne has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Cyclically Adjusted PS Ratio compare to ARWR and CYTK?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #349 out of 538 companies for Cyclically Adjusted PS Ratio. This places Bio-Techne in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.85. Bio-Techne's value of 7.69 is 31.5% above this benchmark. Historically, Bio-Techne's own Cyclically Adjusted PS Ratio has ranged from 6.37 to 34.02 over the past decade. While the company's 10-year median is 14.03 vs. the industry median of 5.85, Bio-Techne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.85, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Cyclically Adjusted PS Ratio of 7.69 is 31.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Cyclically Adjusted PS Ratio is 7.69, which is 45% below median its own 10-year median of 14.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Bio-Techne (MEX:TECH) has a current Cyclically Adjusted PS Ratio of 7.69. The stock's GF Value™ is MXN1,111.68, compared to a current price of MXN1,090.00 — trading 2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 7.69, which is 45% below median its 10-year median of 14.03 and 31.5% above the Biotechnology industry median of 5.85. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Bio-Techne (MEX:TECH), the current Cyclically Adjusted PS Ratio is 7.69 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MEX:TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of MXN1,090.00 is trading 2% below its estimated GF Value™ of MXN1,111.68.
Key valuation signals for MEX:TECH:
Cyclically Adjusted PS Ratio: 7.69 (45% below median its 10-year median of 14.03)
GF Value™: MXN1,111.68 vs. price of MXN1,090.00 (2% below fair value)
Industry Position: 31.5% above the Biotechnology median (#349 of 538)
No single metric tells the full story. See the MEX:TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score
Get the complete analysis for MEX:TECH
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TECH has been successfully added to your 
